查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571659

免疫毒素市场规模、份额和趋势分析报告：2024-2030 年按产品、应用、最终用途、地区和细分市场进行的预测

Immunotoxins Market Size, Share & Trends Analysis Report By Product (Pseudomonas Exotoxin), By Application (Therapy Development), By End-use (Pharmaceutical & Biotechnology Companies),By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

免疫毒素市场成长与趋势：

根据Grand View Research, Inc.的最新报告，预计到2030年，全球免疫毒素市场将达到2.433亿美元，2024年至2030年复合年增长率为8.08%。

癌症盛行率上升和技术进步是预计推动市场成长的一些因素。

免疫毒素是一种标靶治疗，将细胞毒性药物与抗体或生长因子等标靶部分结合。由于免疫毒素在治疗多种癌症和其他疾病方面的潜力，其发展势头强劲。癌症在全世界日益受到关注，预计到 2022 年将有 2,000 万新发病例和 970 万人死亡。免疫毒素由与毒素连接的抗体片段或标靶部分组成，可以选择性地将有毒物质直接递送至癌细胞。此外，免疫毒素的开发和应用在最近的趋势中取得了显着进展，并且正在进行各种研究倡议，旨在提高其功效、降低免疫抗原性并扩大其治疗应用。研究人员正在鑑定新的肿瘤特异性抗原，这些抗原可以作为新的免疫毒素疗法的标靶。

COVID-19 大流行对全球供应链造成了重大破坏。由于卫生法规和劳动力短缺，製造设施面临关闭或营运减少。这种情况影响了生产免疫毒素所需的原料和成分的可用性。此外，疫情促进了製药公司、学术机构和政府机构之间的合作，并加快了药物开发进程，进一步促进了市场成长。

然而，与免疫毒素治疗相关的主要挑战之一是潜在的严重副作用。患者可能会出现噁心、腹泻和发烧等副作用。例如，某些毒素，例如基于蓖麻毒素的免疫毒素，与严重的併发症例如毛细血管渗漏症候群和肝毒性有关。这些风险可能导致临床试验暂停和医药品认证过程中的监管障碍，进一步限制市场成长。

免疫毒素市场报告亮点

  • 按产品划分，白喉毒素（DT）细分市场在2023年占据最大市场占有率，为43.96%。基于 DT 的免疫毒素在针对特定癌细胞方面非常有效，这使得它们对于治疗对化疗和放射线治疗等标准疗法抗药性的癌症很有价值。同时，假单胞菌外毒素（PE）预计在预测期内将以显着的复合年增长率成长。
  • 按应用划分，治疗开发领域预计将在 2023 年占据按应用分類的市场占有率，并在预测期内以最快的复合年增长率增长。
  • 按最终用途划分，製药和生技公司在 2023 年占据最大份额，为 46.40%，预计在预测期内将以最快的复合年增长率成长。但另一方面，学术机构预计在预测期内将以显着的复合年增长率成长。
  • 从地区来看，北美以 41.41% 的份额占据市场主导地位。这是由于生物技术、医学和治疗学方面的强大研究和发展以及政府的大量资助等因素。预计亚太地区在预测期内将以最快的复合年增长率成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章免疫毒素市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/补充市场展望。
  • 市场动态
    • 市场成长要素分析
    • 市场限制因素分析
  • 免疫毒素市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章 免疫毒素市场：依产品估算与趋势分析

  • 细分仪表板
  • 全球免疫毒素市场波动分析：按产品
  • 全球免疫毒素市场规模及趋势分析：依产品分类，2018-2030年
  • 白喉毒素 (DT)
  • 炭疽菌毒素
  • 假单胞菌外毒素 (PE)
  • 其他免疫毒素

第五章免疫毒素市场：按应用估算和趋势分析

  • 细分仪表板
  • 全球免疫毒素市场波动分析：按应用
  • 全球免疫毒素市场规模及趋势分析：依应用分类，2018-2030
  • 生物调查
  • 治疗开发

第六章免疫毒素市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 全球免疫毒素市场波动分析：依最终用途分类
  • 全球免疫毒素市场规模与趋势分析：依最终用途分类，2018-2030
  • 製药和生物技术公司
  • 合约研究官（CRO）和首席行销长（CMO）
  • 学术研究所

第七章免疫毒素市场：按地区估算及趋势分析

  • 市场占有率分析：按地区划分，2023 年和 2030 年
  • 市场仪表板：按地区
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司/竞争对手分类
  • 策略规划
  • 2023 年企业市场分析
  • 公司简介/上市公司
    • Creative Biolabs.
    • List Biological Labs, Inc.
    • The Native Antigen Company
    • Bio-Techne.
    • Abcam Plc.
    • CAYMAN CHEMICAL
    • Merck KGaA
    • Enzo Life Sciences, Inc.
    • Santa Cruz Biotechnology, Inc.
    • Quadratech Diagnostics Ltd.
Product Code: GVR-4-68040-464-4

Immunotoxins Market Growth & Trends:

The global immunotoxins market is anticipated to reach USD 243.3 million by 2030 and is anticipated to expand at a CAGR of 8.08% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of cancer and technological advancements are some of the factors anticipated to drive market growth.

Immunotoxins are a class of targeted therapeutics that combine a cytotoxic agent with a targeting moiety, such as an antibody or growth factor. The development of immunotoxins has gained momentum due to their potential effectiveness in treating various cancers and other diseases. Cancer is a growing concern worldwide, with an estimated 20 million new cases and 9.7 million deaths in 2022. Immunotoxins consist of an antibody fragment, or a targeting moiety linked to a toxin, which allows for selective delivery of the toxic agent directly to cancer cells. Moreover, the development and application of immunotoxins have evolved significantly over recent years, leading to various ongoing research initiatives aimed at improving their efficacy, reducing immunogenicity, and expanding their therapeutic applications. Researchers are identifying novel tumor-specific antigens that could serve as targets for new immunotoxin therapies.

The COVID-19 pandemic led to significant disruptions in global supply chains. Manufacturing facilities faced shutdowns or reduced operations due to health regulations and workforce shortages. This situation affected the availability of raw materials and components necessary for producing immunotoxins. Moreover, the pandemic fostered collaboration among pharmaceutical companies, academic institutions, and government entities to accelerate drug development processes, further propelling market growth.

However, one of the primary challenges associated with immunotoxin therapies is the potential for severe side effects. Patients may experience adverse reactions such as nausea, diarrhea, and fever. For instance, certain toxins like Ricin-based immunotoxins have been associated with severe complications such as capillary leak syndrome or hepatotoxicity. Such risks can lead to clinical trial terminations or regulatory hurdles during drug approval processes, further limiting market growth.

Immunotoxins Market Report Highlights:

  • Based on product, the Diphtheria Toxin (DT) segment held the largest market share of 43.96% in 2023. DT-based immunotoxins are highly effective in targeting specific cancer cells, making them valuable for treating cancers that are resistant to standard therapies like chemotherapy and radiation. On the other hand, Pseudomonas Exotoxin (PE) is anticipated to grow at a significant CAGR over the forecast period.
  • Based on application, in 2023, therapy development segment is anticipated to dominate the market share for the application segment and is anticipated to grow at the fastest CAGR over the forecast period.
  • Based on end-use, pharmaceutical & biotechnology companies segment dominated the end use segment with the largest share of 46.40% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period. However, on the other hand, academic institutes is anticipated to grow at a significant CAGR over the forecast period.
  • Based on region, North America region dominated the market with a share of 41.41% owing to factors such as strong R&D in biotechnology, medicine, and therapeutics, along with substantial government funding. Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Application Segment
    • 1.2.3. End Use Segment
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Immunotoxins Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of cancer
      • 3.2.1.2. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Cytotoxic and manufacturing challenges associated with immunotoxins
  • 3.3. Immunotoxins Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Immunotoxins Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Immunotoxins Market Product Movement Analysis
  • 4.3. Global Immunotoxins Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Diphtheria Toxin (DT)
    • 4.4.1. Diphtheria toxin (DT) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Anthrax Based Toxins
    • 4.5.1. Anthrax based toxins market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Pseudomonas Exotoxin (PE)
    • 4.6.1. Pseudomonas exotoxin (PE) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Other Immunotoxins
    • 4.7.1. Other immunotoxins market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Immunotoxins Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Immunotoxins Market Application Movement Analysis
  • 5.3. Global Immunotoxins Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Biomedical Research
    • 5.4.1. Biomedical research market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Therapy Development
    • 5.5.1. Therapy development market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Immunotoxins Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Immunotoxins Market End Use Movement Analysis
  • 6.3. Global Immunotoxins Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biotechnology Companies
    • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. CROs & CMOs
    • 6.5.1. CROs & CMOs market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Academic & Research Institutes
    • 6.6.1. Academic & research institutes market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Immunotoxins Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Competitive scenario
      • 7.4.1.3. Regulatory framework
      • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Norway
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Sweden
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Competitive scenario
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Competitive scenario
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Competitive scenario
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Competitive scenario
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Creative Biolabs.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. List Biological Labs, Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. The Native Antigen Company
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Bio-Techne.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Abcam Plc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. CAYMAN CHEMICAL
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Merck KGaA
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Enzo Life Sciences, Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Santa Cruz Biotechnology, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Quadratech Diagnostics Ltd.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global immunotoxins market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 4 Global immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 9 North America immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 11 U.S. immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 12 U.S. immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Canada immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 14 Canada immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 15 Canada immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Mexico immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 17 Mexico immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 18 Mexico immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 21 Europe immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Germany immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 24 Germany immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 25 Germany immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 26 UK immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 27 UK immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 28 UK immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 29 France immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 30 France immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 31 France immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Italy immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 33 Italy immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 34 Italy immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Spain immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 36 Spain immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 37 Spain immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Denmark immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 39 Denmark immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 40 Denmark immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Sweden immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 42 Sweden immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 43 Sweden immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Norway immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 45 Norway immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 46 Norway immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 51 China immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 52 China immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 53 China immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Japan immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 55 Japan immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 56 Japan immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 57 India immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 58 India immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 59 India immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 60 South Korea immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 61 South Korea immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 62 South Korea immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 63 Australia immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 64 Australia immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 65 Australia immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Thailand immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 67 Thailand immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 68 Thailand immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Latin America immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 71 Latin America immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 72 Latin America immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 73 Brazil immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 74 Brazil immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 75 Brazil immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 76 Argentina immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 77 Argentina immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 78 Argentina immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 79 MEA immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 80 MEA immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 81 MEA immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 82 MEA immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 83 South Africa immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 84 South Africa immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Africa immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 89 UAE immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 90 UAE immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 91 UAE immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 93 Kuwait immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait immunotoxins market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Immunotoxins market: Market outlook
  • Fig. 5 Immunotoxins market: Segment outlook
  • Fig. 6 Immunotoxins market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Immunotoxins market driver impact
  • Fig. 9 Immunotoxins market restraint impact
  • Fig. 10 Immunotoxins market: Product outlook and key takeaways
  • Fig. 11 Immunotoxins market: Product movement analysis
  • Fig. 12 Diphtheria toxin (DT) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Anthrax based toxins market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Pseudomonas exotoxin (PE) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Other immunotoxins market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Immunotoxins market: Application outlook and key takeaways
  • Fig. 17 Immunotoxins market: Application movement analysis
  • Fig. 18 Biomedical research market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Therapy development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Immunotoxins market: End Use outlook and key takeaways
  • Fig. 21 Immunotoxins market: End Use movement analysis
  • Fig. 22 Pharmaceutical & biotechnology companies market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 23 CROs & CMOs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Global immunotoxins market: Regional outlook and key takeaways
  • Fig. 26 Global immunotoxins market: Regional movement analysis
  • Fig. 27 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Key country dynamics
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Key country dynamics
  • Fig. 31 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Key country dynamics
  • Fig. 33 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Key country dynamics
  • Fig. 36 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Key country dynamics
  • Fig. 38 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)